<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2395">
  <stage>Registered</stage>
  <submitdate>9/06/2009</submitdate>
  <approvaldate>9/06/2009</approvaldate>
  <nctid>NCT00918034</nctid>
  <trial_identification>
    <studytitle>Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)</studytitle>
    <scientifictitle>A Phase 2 Study to Evaluate the Safety and Effectiveness of Using the Litx BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Who Are Candidates for Interventional Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>LSO-OL012</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Benign Prostatic Hyperplasia</healthcondition>
    <healthcondition>Lower Urinary Tract Symptoms</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - talaporfin sodium
Treatment: devices - Transurethral illumination with light emitting diodes
Treatment: surgery - Placement

Experimental: LS11 (talaporfin sodium) - 


Treatment: drugs: talaporfin sodium
LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes)

Treatment: devices: Transurethral illumination with light emitting diodes
A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes

Treatment: surgery: Placement
Placement of device in prostate urethra

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: devices</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety of light-activated talaporfin sodium by recording of Adverse Events; Preliminary effectiveness of light-activated talaporfin sodium by evaluating the International Prostate Symptom Score (IPSS) along with Bother Score (BS).</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Males, aged 50 years or older with prior diagnosis of BPH;

          2. Patients may be eligible whether or not they are on medication for LUTS due to BPH.

          3. Patients who are candidates for interventional therapy;

          4. Patients who understand and have the ability to sign written informed consent prior to
             any study procedures and/or discontinuation of exclusionary medications;

          5. Patients with an International Prostate Symptom Score of = 15 points;

          6. Patients with moderate to severe BPH (Bother Score = 3);

          7. Maximum urinary flow rate (Qmax) = 15 mL/sec;

          8. Post void residual volume (PVR) = 300 mL;

          9. Length of prostatic urethra = 4.0 cm.</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patients with any previous minimally invasive or surgical intervention for BPH.

          2. Patients who are currently enrolled in or who have enrolled in another clinical trial
             for any disease within the past 30 days.

          3. Patients with an active urinary tract infection.

          4. Patients with a urethral stricture.

          5. Patients with interstitial cystitis.

          6. Patients with a predominant middle lobe obstruction.

          7. Patients who have evidence or history of prostate or bladder cancer or carcinoma in
             situ of the bladder.

          8. Patients with an abnormal digital rectal exam suggestive of carcinoma of the prostate.

          9. Patients with an abnormal digital rectal exam suggestive of an indurated nodule.

         10. Patients with a PSA of &gt; 10 ng/ml. If the PSA is 4-10 ng/ml, local standard of care
             should be pursued to ensure the possibility of prostate cancer is followed up and
             ruled out prior to, entry into the study.

         11. Patients who had a biopsy of the prostate within the past 6 weeks.

         12. Patients with bleeding diathesis.

         13. Patients with clinically significant renal or hepatic impairment.

         14. Patients with neurological conditions felt to affect the bladder or a history of a
             neurogenic or chronically decompensated bladder.

         15. Patients who daily use a pad or device for incontinence.

         16. Patients who had an episode of unstable angina pectoris, myocardial infarction,
             transient ischemic attack, or cerebrovascular accident (stroke) within the past 6
             months, or peripheral arterial disease with intermittent claudication or Leriches
             syndrome.

         17. Patient has an interest in future fertility.

         18. Patients with prolonged QT interval at baseline and/or who are currently taking
             medication that prolongs QT interval ("prolonged QT interval" defined as &gt; 450 ms).

         19. Inadequate organ function as evidenced by the following: Platelet count &lt;100,000/mm3;
             WBC &lt;4,000/mm3; Neutrophils &lt;1,800/mm3; Hemoglobin &lt;10 g/dL; AST and ALT &gt;3 x ULN;
             Creatinine &gt;1.5 x ULN

         20. Known sensitivity to porphyrin-type drugs or known history of porphyria.

         21. Inability to avoid bright indoor lighting and sunlight during the first 72 hours after
             LS11 administration.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>21</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Brisbane and Women's Hospital Center of Clinical Research - Herston</hospital>
    <hospital>Bayside Urology - Mentone</hospital>
    <hospital>Princess Alexandra Hospital - Wolloongabba</hospital>
    <postcode> - Herston</postcode>
    <postcode> - Mentone</postcode>
    <postcode>QLD 4102 - Wolloongabba</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Nelson</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Tauranga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Whangarei</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Light Sciences Oncology</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a phase 2 study to evaluate the safety and effectiveness of light-activated
      talaporfin sodium in patients with LUTS due to benign prostatic hyperplasia (BPH).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00918034</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sy-Shi Wang, PhD</name>
      <address>Light Sciences Oncology</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>